Phase II study of Ninjin'yoeito for anorexia in patients with advanced non-small-cell lung cancer

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs041220102

Enrollment

Registered

2022-12-09

Start date

2022-12-09

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced non-small-cell lung cancer

Interventions

Ninjin'yoeito prescription

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Age >= 18-year-old 2) Anorexia (SNAQ score >=14 points) 3) ECOG-PS 0-2 4) Expected survival time>= 12 weeks 5) Written informed consent 6) Advanced non-small-cell lung cancer in stage Ill/IV 7) Meets the following test results 1. Hb >= 8.0 g/dl 2. T-Bil =90% or Pa02 >= 60 Torr

Exclusion criteria

Exclusion criteria: (1) Receiving cytotoxic chemotherapy within two weeks (2) Planning to start cytotoxic chemotherapy during the study period (3) Unable to eat or drink food or take medicines (4) Treatable causes of anorexia, including electrode abnormalities, peptic ulcer, severe constipation, intracranial disease, psychosis, etc.

Design outcomes

Primary

Measure	Time frame
Change in anorexia score (SNAQ score)	—

Secondary

Measure	Time frame
Changes in weight, BMI, fatigue scale, depression/anxiety scale, safety, and compliance.	—

Contacts

Public ContactTateaki Naito

Shizuoka Cancer Center

t.naito@scchr.jp+81-55-989-5222

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026